 "Nandini Piramal, chairperson Piramal Pharma")
After it posted a 12 per cent revenue growth for the financial year 2024-25 (FY25), Piramal Pharma (PPL) expects single-digit growth in the current financial year with a muted Ebitda. The company has presence across contract development and manufacturing, complex hospital generics as well as consumer health business in India.
Speaking to Business Standard, Chairperson of PPL Nandini Piramal said FY26 was set to be a ‘muted year’ owing to a lot of uncertainties and it was important to watch out for macro factors like trade deals and tariff environments. PPL posted a 12 per cent rise in revenues to
